Business Context and Reporting Period
This Form 8-K Current Report was filed by Proteon Therapeutics, Inc. on October 18, 2016. The filing reports a corporate governance event involving the appointment of a new Chairman of the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Paul J. Hastings as a member and Chairman of the Board of Directors, effective October 18, 2016. Mr. Hastings was also appointed as Chairman of the Governance and Nominating Committee. The Board determined that Mr. Hastings qualifies as "independent" under NASDAQ and SEC rules.
Compensation and Governance Details
- Term: Mr. Hastings serves in the second class of directors, with a term expiring at the 2019 Annual Meeting of Stockholders.
- Cash Compensation: He will receive annual cash retainers consistent with the Company's 2016 proxy statement for non-employee directors.
- Equity Grant: On October 18, 2016, the Board granted an option to purchase 13,333 shares of common stock. These shares vest annually over three years from the grant date.
- Indemnification: The Company plans to enter into a standard Indemnification Agreement with Mr. Hastings.
Investor Verification Checklist
- Verify the independence status of Paul J. Hastings as disclosed in the filing.
- Review the specific vesting schedule and terms of the 13,333 stock options granted.
- Confirm the details of the annual cash retainers by referencing the Company's 2016 proxy statement.
- Check for any related party transactions involving Mr. Hastings or his immediate family members.